CR6736A - 5-ALQUILPIRIDO [2,3-D [PIRIDINES AS INHIBITORS OF TYPOSINE KINASA - Google Patents

5-ALQUILPIRIDO [2,3-D [PIRIDINES AS INHIBITORS OF TYPOSINE KINASA

Info

Publication number
CR6736A
CR6736A CR6736A CR6736A CR6736A CR 6736 A CR6736 A CR 6736A CR 6736 A CR6736 A CR 6736A CR 6736 A CR6736 A CR 6736A CR 6736 A CR6736 A CR 6736A
Authority
CR
Costa Rica
Prior art keywords
inhibitors
typosine
alquilpirido
piridines
kinasa
Prior art date
Application number
CR6736A
Other languages
Spanish (es)
Inventor
John Booth Richard
Myra Dobrusin Ellen
Laurence Toogood Peter
Norman Vanderwel Scott
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of CR6736A publication Critical patent/CR6736A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se refiere a compuestos utiles para el tratamiento de trastornos de la proliferacion celular como cancer, arteroclerosis, y restenosis. Estos compuestos son inhibidores potentes de kinasas dependientes de ciclina y de kinasas reguladas por factores de crecimiento.It refers to compounds useful for the treatment of cell proliferation disorders such as cancer, atherosclerosis, and restenosis. These compounds are potent inhibitors of cyclin dependent kinases and kinases regulated by growth factors.

CR6736A 2000-03-06 2002-08-23 5-ALQUILPIRIDO [2,3-D [PIRIDINES AS INHIBITORS OF TYPOSINE KINASA CR6736A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18712400P 2000-03-06 2000-03-06

Publications (1)

Publication Number Publication Date
CR6736A true CR6736A (en) 2004-03-10

Family

ID=22687699

Family Applications (1)

Application Number Title Priority Date Filing Date
CR6736A CR6736A (en) 2000-03-06 2002-08-23 5-ALQUILPIRIDO [2,3-D [PIRIDINES AS INHIBITORS OF TYPOSINE KINASA

Country Status (37)

Country Link
EP (1) EP1268476A1 (en)
JP (1) JP2003528101A (en)
KR (1) KR20020075805A (en)
CN (1) CN1422268A (en)
AP (1) AP2002002643A0 (en)
AR (1) AR034119A1 (en)
AU (1) AU2001233028A1 (en)
BG (1) BG107161A (en)
BR (1) BR0109056A (en)
CA (1) CA2401368A1 (en)
CO (1) CO5280200A1 (en)
CR (1) CR6736A (en)
CZ (1) CZ20022929A3 (en)
DZ (1) DZ3308A1 (en)
EA (1) EA200200802A1 (en)
EE (1) EE200200506A (en)
GT (1) GT200100037A (en)
HN (1) HN2001000040A (en)
HR (1) HRP20020798A2 (en)
HU (1) HUP0300136A2 (en)
IL (1) IL151480A0 (en)
IS (1) IS6524A (en)
MA (1) MA26881A1 (en)
MX (1) MXPA02008535A (en)
NO (1) NO20024235L (en)
NZ (1) NZ520962A (en)
OA (1) OA12227A (en)
PA (1) PA8513201A1 (en)
PE (1) PE20011177A1 (en)
PL (1) PL358271A1 (en)
PY (1) PY0104899A (en)
SK (1) SK12472002A3 (en)
SV (1) SV2001000338A (en)
TN (1) TNSN01036A1 (en)
WO (1) WO2001070741A1 (en)
YU (1) YU66502A (en)
ZA (1) ZA200207110B (en)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
JP4524072B2 (en) 2000-10-23 2010-08-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー New compounds
CZ20032416A3 (en) * 2001-02-12 2004-07-14 F. Hoffmann-La Roche Ag 6-Substituted pyridopyrimidines
JP4166991B2 (en) * 2001-02-26 2008-10-15 田辺三菱製薬株式会社 Pyridopyrimidine or naphthyridine derivatives
AU2002324450A1 (en) * 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidines and uses thereof
US20030100572A1 (en) * 2001-06-21 2003-05-29 Ariad Pharmaceuticals,Inc. Novel pyridopyrimidones and uses thereof
DE60303009T2 (en) 2002-01-22 2006-07-13 Warner-Lambert Co. Llc 2- (pyridin-2-ylamino) -pyrido [2,3-d] pyrimidine-7-ONE
MXPA04010267A (en) 2002-04-19 2005-02-03 Smithkline Beecham Corp Novel compounds.
EP1542989B1 (en) 2002-07-31 2007-04-18 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
AU2003273675A1 (en) 2002-10-09 2004-05-04 Wayne R. Danter Protein tyrosine kinase inhibitors
JP2006516561A (en) * 2003-01-17 2006-07-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 2-Aminopyridine substituted heterocycles as inhibitors of cell proliferation
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
JP4053073B2 (en) * 2003-07-11 2008-02-27 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Isethionate, a selective CDK4 inhibitor
CA2536954C (en) 2003-08-29 2012-11-27 Exelixis, Inc. C-kit modulators and methods of use
WO2005047284A1 (en) 2003-11-13 2005-05-26 F. Hoffmann-La Roche Ag Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
DE102004029784A1 (en) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel 2-Benzylaminodihydropteridinones, process for their preparation and their use as medicaments
DE102004033670A1 (en) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg New pyridodihydropyrazinone, process for its preparation and its use as a medicament
FR2873118B1 (en) 2004-07-15 2007-11-23 Sanofi Synthelabo PYRIDO-PYRIMIDINE DERIVATIVES, THEIR APPLICATION IN THERAPEUTICS
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
EP1630163A1 (en) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinones, methods for their preparation and their use as drugs
CA2575804A1 (en) * 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones used as plk (polo like kinase) inhibitors
DE102004058337A1 (en) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for the preparation of fused piperazin-2-one derivatives
WO2006076706A1 (en) 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
MY145343A (en) 2005-03-25 2012-01-31 Glaxo Group Ltd Novel compounds
US20090137550A1 (en) 2005-03-25 2009-05-28 Glaxo Group Limited Novel Compounds
PE20061193A1 (en) 2005-03-25 2006-12-02 Glaxo Group Ltd DERIVATIVES OF 3,4-DIHYDROPYRIMIDO [4,5-d] PYRIMIDIN-2- [1H] -0NA AS KINASE INHIBITORS p38
US20080096905A1 (en) 2005-03-25 2008-04-24 Glaxo Group Limited Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
FR2887882B1 (en) * 2005-07-01 2007-09-07 Sanofi Aventis Sa PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
US8247408B2 (en) * 2005-10-07 2012-08-21 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
US8044062B2 (en) * 2005-10-07 2011-10-25 Exelixis, Inc. Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha
FR2896246B1 (en) 2006-01-13 2008-08-15 Sanofi Aventis Sa PYRIDO-PYRIMIDONE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
GEP20115306B (en) 2006-09-15 2011-10-10 Pfizer Prod Inc
BRPI0715566A2 (en) * 2006-10-16 2013-07-02 Gpc Biotech Inc compound, prodrug, pharmaceutical composition, use of a compound, method for inhibiting cell proliferation and method for synthesizing a compound
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
US20080114007A1 (en) * 2006-10-31 2008-05-15 Player Mark R 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
FR2910813B1 (en) 2006-12-28 2009-02-06 Sanofi Aventis Sa NEW THERAPEUTIC USE FOR THE TREATMENT OF LEUKEMIA
WO2008124323A1 (en) * 2007-04-03 2008-10-16 Array Biopharma Inc. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
CN101784551A (en) * 2007-06-15 2010-07-21 万有制药株式会社 Dicycloaniline Derivatives
EP2185559A1 (en) 2007-08-03 2010-05-19 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
WO2009085185A1 (en) 2007-12-19 2009-07-09 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
EP2225226B1 (en) 2007-12-26 2016-08-17 Critical Outcome Technologies, Inc. Compounds and their use in a method for treatment of cancer
EP2100894A1 (en) * 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
MX2010010975A (en) * 2008-04-07 2010-11-01 Amgen Inc Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors.
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
EP3023426A1 (en) 2008-07-17 2016-05-25 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
AR073524A1 (en) 2008-09-30 2010-11-10 Exelixis Inc PI3K A AND M TOR INHIBITING PYRIDOPIRIMIDINONES
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
CA2776770A1 (en) * 2009-10-09 2011-04-14 Afraxis, Inc. 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
CA2784749C (en) 2009-12-18 2017-12-12 E. Premkumar Reddy Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof
AR080151A1 (en) 2010-02-09 2012-03-14 Exelixis Inc METHODS TO TREAT CANCER USING PI 3K PYRIDOPIRIMIDINONE INHIBITORS AND MTOR IN COMBINATION WITH AUTOPHAGIA INHIBITORS
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
DK2600719T3 (en) * 2010-08-05 2014-12-15 Univ Temple 2-Substituted 8-alkyl-7-oxo-7,8-dihydropyrido [2,3-d] pyrimidine-6-carbon nitriles and uses thereof
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
JP6000273B2 (en) 2010-11-29 2016-09-28 オーエスアイ・ファーマシューティカルズ，エルエルシー Macrocyclic kinase inhibitor
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
PT2688887E (en) 2011-03-23 2015-07-06 Amgen Inc TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3
US8962831B2 (en) * 2011-05-17 2015-02-24 Principia Biopharma Inc. Tyrosine kinase inhibitors
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
EP2817308B1 (en) * 2012-02-23 2016-09-07 AbbVie Inc. Pyridopyrimidinone inhibitors of kinases
PL2958916T3 (en) * 2013-02-21 2019-01-31 Pfizer Inc. Solid forms of a selective cdk4/6 inhibitor
WO2015011236A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
WO2016015598A1 (en) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
TWI646094B (en) * 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
JP6563623B1 (en) 2016-08-15 2019-08-21 ファイザー・インク Pyridopyrimidinone CDK2 / 4/6 inhibitor
AU2018229148B2 (en) * 2017-03-03 2022-08-04 Auckland Uniservices Limited FGFR kinase inhibitors and pharmaceutical uses
US11174252B2 (en) 2018-02-15 2021-11-16 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
WO2020114519A1 (en) * 2018-12-07 2020-06-11 杭州英创医药科技有限公司 Heterocyclic compound as cdk-hdac dual pathway inhibitor
CN112759589B (en) * 2019-11-01 2022-04-08 暨南大学 Pyrimidopyridinones and their use
US11697648B2 (en) 2019-11-26 2023-07-11 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as JAK inhibitors
JP7756374B2 (en) * 2021-03-08 2025-10-20 曁南大学 Pyridopyrimidine compounds and their uses
WO2022258023A1 (en) * 2021-06-09 2022-12-15 郑州同源康医药有限公司 Compound as cdk kinase inhibitor and use thereof
CN117720531A (en) * 2022-09-16 2024-03-19 华东师范大学 Pyridonopyrimidine derivatives as RSK inhibitors and their applications
EP4617267A4 (en) * 2022-11-10 2026-02-18 Prime Gene Therapeutics Co Ltd Thioether compound with soft active ingredient properties and use thereof, as well as pharmaceutical composition and use thereof
WO2024107730A1 (en) * 2022-11-14 2024-05-23 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
DE69839338T2 (en) * 1997-02-05 2008-07-10 Warner-Lambert Company Llc PYRIDO (2,3-D) PYRIMIDINE AND 4-AMINO-PYRIMIDINE AS INHIBITORS OF CELLULAR PROLIFERATION
EE200000706A (en) * 1998-05-26 2002-06-17 Warner-Lambert Company Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cell proliferation

Also Published As

Publication number Publication date
PY0104899A (en) 2003-11-03
CZ20022929A3 (en) 2003-02-12
AU2001233028A1 (en) 2001-10-03
NO20024235D0 (en) 2002-09-05
MXPA02008535A (en) 2002-12-13
NZ520962A (en) 2003-09-26
NO20024235L (en) 2002-11-05
OA12227A (en) 2004-03-18
YU66502A (en) 2005-09-19
EE200200506A (en) 2004-02-16
HN2001000040A (en) 2001-09-06
IS6524A (en) 2002-08-23
EA200200802A1 (en) 2003-02-27
CA2401368A1 (en) 2001-09-27
BR0109056A (en) 2003-06-03
ZA200207110B (en) 2003-12-04
TNSN01036A1 (en) 2005-11-10
CN1422268A (en) 2003-06-04
IL151480A0 (en) 2003-04-10
PE20011177A1 (en) 2001-11-23
HUP0300136A2 (en) 2003-05-28
MA26881A1 (en) 2004-12-20
JP2003528101A (en) 2003-09-24
BG107161A (en) 2003-06-30
EP1268476A1 (en) 2003-01-02
SK12472002A3 (en) 2003-04-01
SV2001000338A (en) 2001-11-30
KR20020075805A (en) 2002-10-05
GT200100037A (en) 2002-03-04
DZ3308A1 (en) 2001-09-27
HRP20020798A2 (en) 2004-02-29
WO2001070741A1 (en) 2001-09-27
CO5280200A1 (en) 2003-05-30
PL358271A1 (en) 2004-08-09
AP2002002643A0 (en) 2002-12-31
PA8513201A1 (en) 2003-06-30
AR034119A1 (en) 2004-02-04

Similar Documents

Publication Publication Date Title
CR6736A (en) 5-ALQUILPIRIDO [2,3-D [PIRIDINES AS INHIBITORS OF TYPOSINE KINASA
AR030044A1 (en) PIRIDO (2,3-D) PIRIMIDIN-2,7-KINASE INHIBITING DIAMINS
GT200300087A (en) 2- (2,6-DICLOROPHENYL) -DIARYLIMIDAZOLS
ECSP088145A (en) BICYCLIC DERIVATIVES AS INHIBITORS OF CINASA P38
MY141867A (en) Substituted pyrimidines useful as protein kinase inhibitors
BRPI0406809A (en) 2-Aminopyridine substituted heterocycles as cell proliferation inhibitors
CR20130506A (en) PIRROL [2,3-b] PIRIDINES AND PIRROL [2,3-b] HETEROARILO PYRIMIDINES REPLACED AS INHIBITORS OF JANUS KINASES (DIVISIONAL EXP. 10065)
SV2002000572A (en) 2- (4-PIRIDIL) ANIMO- 6- DIALCOXIFENIL-PIRIDO [2,3-D] PIRIMIDIN-7-ONAS
ECSP045201A (en) 2- (PIRIDIN-2-ILAMINO) -PIRIDO [2,3-d] PIRIMIDIN-7-ONAS
MXPA04002983A (en) Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors.
CR9663A (en) 1,4-DIHYDROPIRIDINE-CONDENSED HETEROCICLES, PROCESSES TO PREPARE THE SAME, USE AND COMPOSITIONS CONTAINING THEM
UY27225A1 (en) INHIBITORS OF RHO-QUINASA
TNSN05007A1 (en) Novel thiophenylglycoside derivatives, methods for production thereof, medicaments comprising said compounds and use thereof.
HN2002000067A (en) INHIBITORS OF THE RHO - QUINASA.
PT1325011E (en) METHODS AND COMPOUNDS FOR TREATMENT OF PROLIFERATIVE DISEASES
GT200200190A (en) SUBSTITUTED BENZIMIDAZOL COMPOUNDS AND ITS USE IN CANCER TREATMENT
TNSN07440A1 (en) Derivatives of pyrido [2,3 -d] pyrimidine, the preparation thereof, and the therapeutic application of the same
WO2003039545A3 (en) Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers
IL151692A0 (en) Polyamine analogues as cytotoxic agents
BR0309053A (en) Compounds
CR8749A (en) PIRIMIDINE DERIVATIVES TO TREAT ANOMALO CELLULAR GROWTH
DE60100855D1 (en) 1,8-NAPHTHALIMID IMIDAZO [4,5,1-DE] ACRIDONE WITH ANTITUARY EFFECT
EP1615897A4 (en) Pyrimidinone compounds as calcilytics
UY26559A1 (en) PIRIDOL [2,3-D] PIRIMIDIN-2,7-DIAMINES KINASE INHIBITORS
UA81420C2 (en) Process for the preparation of substituted pyrimidines and pyrimidine derivatives as inhibitors of protein kinase

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)